The role of lipid metabolism disorders, atypical isoforms of protein kinase C, and mutational status of cytosolic and mitochondrial forms of isocitrate dehydrogenase in carcinogenesis of glial tumors

Nikitin P.V.; Potapov A.A.; Ryzhova M.V.; Shurkhaĭ V.A.; Kulikov E.E.; Zhvanskiy E.S.; Popov I.A.; Nikolaev E.N.

doi:https://doi.org/10.17116/neiro2018823112

Close metadata

Recommended articles:

Glymphatic system in health and disease: a narrative review. Burdenko's Journal of Neurosurgery. 2025;(4):112-118

TERTp mutation screening using digital droplet PCR of collection of 52 paired DNA samples from blood plasma and tumor tissue in patients with glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(5):87-95

Surgical treatment of glial tumors of the frontal lobe. Current state of the problem. Part I: motor functional system. Burdenko's Journal of Neurosurgery. 2025;(5):115-121

Surgery for gliomas of Broca’s area. Burdenko's Journal of Neurosurgery. 2025;(6):38-45

Surgical treatment of intracerebral frontal lobe tumors. Part II: speech functional system. Burdenko's Journal of Neurosurgery. 2025;(6):114-119

Pilocytic astrocytomas with aggressive clinical course: a single-center experience. Burdenko's Journal of Neurosurgery. 2025;(6-2):29-37

Aptamer-based conjugated molecules in experimental and clinical approaches to treatment of glioblastoma. Burdenko's Journal of Neurosurgery. 2025;(6-2):44-49

A «Trojan horse» for glioblastoma: targeted aptamer delivery strategy. Burdenko's Journal of Neurosurgery. 2025;(6-2):50-56

Lipid profile indicators and their ratios in patients with non-ST elevation acute coronary syndrome. Russian Cardiology Bulletin. 2025;(3):48-53

Comparative analysis of the placental proteome in normal and severe preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):5-14

Abstract:

The relationship between molecular genetic and metabolic disorders is one of the challenges of modern oncology. In this review, we consider lipid metabolism and its changes as one of the factors of oncogenesis of glial tumors. Also, we demonstrate that the genome and the metabolome are interconnected by a large number of links, and the metabolic pathways, during their reorganization, are able to drastically affect the genetic structure of the cell and, in particular, cause its tumor transformation. Our own observations and analysis of the literature data allow us to conclude that mass spectrometry is a highly accurate current method for assessing metabolic disorders at the cellular level. The use of mass spectrometry during surgery allows the neurosurgeon to obtain real-time data on the level of specific molecular markers in the resected tissue, thereby bringing intraoperative navigation techniques to the molecular level. The generation of molecular fingerprints for each tumor significantly complements the available neuroimaging, molecular genetic, and immunohistochemical data.

Keywords:

neuro-oncology

lipids

oncogenesis

IDH1

IDH2

glioma

protein kinase C (PKC)

mass spectrometry

Authors:

Nikitin P.V.

Burdenko Neurosurgery Institute, 4-ya Tverskaya-Yamskaya Str., 16, Moscow, Russia, 125047

Potapov A.A.

NII neĭrokhirurgii im. akad. N.N. Burdenko RAMN, Moskva

Ryzhova M.V.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko" RAMN, Moskva

ORCID: 0000-0001-7206-6365

Shurkhaĭ V.A.

NII neĭrokhirurgii im. akad. N.N. Burdenko RAMN, Moskva

Kulikov E.E.

Moscow Institute of Physics and Technology, Institutskiy Pereulok, 9, Dolgoprudny, Moscow Region, Russia, 141701;
Federal Research Center «Fundamentals of Biotechnology», Leninskiy Prospect, 33/2, Moscow, Russia, 119071

Zhvanskiy E.S.

Moscow Institute of Physics and Technology, Institutskiy Pereulok, 9, Dolgoprudny, Moscow Region, Russia, 141701

Popov I.A.

Moscow Institute of Physics and Technology, Institutskiy Pereulok, 9, Dolgoprudny, Moscow Region, Russia, 141701

Nikolaev E.N.

Moscow Institute of Physics and Technology, Institutskiy Pereulok, 9, Dolgoprudny, Moscow Region, Russia, 141701;
Skolkovo Institute of Science and Technology, Nobelya Str., 3, Moscow, Russia, 143026;
Institute of Energy Problems of Chemical Physics, Leninskiy Prospect, 38/2, Moscow, Russia, 119334

Close metadata

References:

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16:7:896-913. https://doi.org/10.1093/neuonc/nou087
Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007—2011. Neuro Oncol. 2014;16(Suppl 4): iv1-iv63. https://doi.org/10.1093/neuonc/nou223
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:6:803-820. https://doi.org/10.1007/s00401-016-1545-1
Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015;152:63-82. https://doi.org/10.1016/j.pharmthera.2015.05.005
Soffietti R, Franchino F, Magistrello M, Pellerino A, Ruda R. Perspectives of personalized chemotherapy of gliomas based on molecular tumor profiling. Prog Neurol Surg. 2018;31:168-179. https://doi.org/10.1159/000467378
Mrugala MM. Advances and challenges in the treatment of glioblastoma: a clinician’s perspective. Discov Med. 2013;15:83:221-230.
Dubey S, Janu A, Chaudhari S, Moiyadi A. Navigable 3D-ultrasound facilitates supra-radical resections beyond the contrast-enhancing boundaries in malignant gliomas. J Neurol Surg A Cent Eur Neurosurg. 2016;77(4):372-375. https://doi.org/10.1055/s-0035-1570005
Zinn PO, Colen RR, Kasper EM, Burkhardt JK. Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients. Int J Oncol. 2013;42(3):929-934. https://doi.org/10.3892/ijo.2013.1770
Emmanuel C, Lawson T, Lelotte J, Fomekong E, Vaz G, Renard L, Whenham N, Raftopoulos C. Long-term survival after glioblastoma resection: hope despite poor prognosis factors. J Neurosurg Sci. 2018. https://doi.org/10.23736/s0390-5616.18.04180-2
Eyupoglu IY, Hore N, Merkel A, Buslei R, Buchfelder M, Savaskan N. Supra-complete surgery via dual intraoperative visualization approach (DiVA) prolongs patient survival in glioblastoma. Oncotarget. 2016;7(18):25755-25768. https://doi.org/10.18632/oncotarget.8367
Kobyakov GL, Bekyashev AKh, Golanov AV, Konovalov AN, Naskhletashvili DR, Potapov AA, Rzayev DA, Ryzhova MV, Smolin AV, Trunin YuYu, Ulitin AYu. Practical recommendations on the drug treatment of primary tumors of the central nervous system. Malignant tumors. RUSSCO Practical guidelines. 2017;7:77-92. (In Russ.) https://doi.org/10.18027/2224–5057–2017–7–3s2–77–92
Shurkhay VA, Goryaynov SA, Aleksandrova EV, Spallone A, Potapov AA. Navigation systems in neurosurgery. Zh Vopr Neirokhir Im N.N. Burdenko. 2016;80(6):107-114. (In Russ.) https://doi.org/10.17116/neiro2016806107-114
Shurhaj VA, Goryajnov SA, Kutin MA, Eolchiyan SA, Kapitanov DN, Fomichev DV, Kalinin PL, Shkarubo AN, Kopachev DN, Melikyan AG, Nersesyan MV, Shkatova AM, Konovalov AN, Potapov AA. Application of intraoperative electromagnetic frameless navigation in transcranial and endoscopic neurosurgical interventions. Zh Vopr Neirokhir Im N N Burdenko. 2017;81(5):5-16. https://doi.org/10.17116/neiro20178155-16
Eberlin LS, Dill AL, Golby AJ, Ligon KL, Wiseman JM, Cooks RG, Agar NY. Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry. Angew Chem Int Ed Engl. 2010;49(34):5953-5956. https://doi.org/10.1002/anie.201001452
Zhvansky ES, Sorokin AA, Popov IA, Shurkhay VA, Potapov AA, Nikolaev EN. High-resolution mass spectra processing for the identification of different pathological tissue types of brain tumors. Eur J Mass Spectrom (Chichester). 2017;23(4):213-216. https://doi.org/10.1177/1469066717721484
Kononikhin A, Zhvansky E, Shurkhay V, Popov I, Bormotov D, Kostyukevich Y, Karchugina S, Indeykina M, Bugrova A, Starodubtseva N, Potapov A, Nikolaev E. A novel direct spray-from-tissue ionization method for mass spectrometric analysis of human brain tumors. Anal Bioanal Chem. 2015;407(25):7797-7805. https://doi.org/10.1007/s00216-015-8947-0
Sorokin A, Zhvansky E, Shurkhay V, Bocharov K, Popov I, Levin N, Zubtsov D, Bormotov D, Kostyukevich Y, Potapov A, Nikolaev E. Feature selection algorithm for spray-from-tissue mass spectrometry. Eur J Mass Spectrom (Chichester). 2017;23(4):237-241. https://doi.org/10.1177/1469066717721843
Eberlin LS, Norton I, Dill AL, Golby AJ, Ligon KL, Santagata S, Cooks RG, Agar NY. Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res. 2012;72(3):645-654. https://doi.org/10.1158/0008-5472.Can-11-2465
Eberlin LS, Norton I, Orringer D, Dunn IF, Liu X, Ide JL, Jarmusch AK, Ligon KL, Jolesz FA, Golby AJ, Santagata S, Agar NY, Cooks RG. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci USA. 2013;110(5): 1611-1616. https://doi.org/10.1073/pnas.1215687110
Brante G. Studies on lipids in the nervous system with special reference to quantitative chemical determination and topical distribution. Acta Physiol Scand. 1949;18(63).
Gopal K, Grossi E, Paoletti P, Usardi M. Lipid composition of human intracranial tumors: a biochemical study. Acta Neurochir (Wien). 1963; 11:333-347.
Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta. 2011;1807(6):726-734.
Lin H, Patel S, Affleck VS, Wilson I, Turnbull DM, Joshi AR, Maxwell R, Stoll EA. Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro Oncol. 2017;19(1):43-54. https://doi.org/10.1093/neuonc/now128
Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, Jindal A, Jeffrey FM, Choi C, Madden C, Mathews D, Pascual JM, Mickey BE, Malloy CR, DeBerardinis RJ. Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed. 2012;25(11):1234-1244. https://doi.org/10.1002/nbm.2794
Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, Huang Z, Barnett S, Mickey BE, DeBerardinis RJ, Tu BP, Maher EA, Bachoo RM. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603-1614. https://doi.org/10.1016/j.cell.2014.11.025
Tao BB, He H, Shi XH, Wang CL, Li WQ, Li B, Dong Y, Hu GH, Hou LJ, Luo C, Chen JX, Chen HR, Yu YH, Sun Q, Lu YC. Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. J Clin Neurosci. 2013;20(5):717-720. https://doi.org/10.1016/j.jocn.2012.03.050
Currie E, Schulze A, Zechner R, Walther TC, Farese RVJr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153-161. https://doi.org/10.1016/j.cmet.2013.05.017
Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52(4):585-589. https://doi.org/10.1016/j.plipres.2013.08.005
Liu Q, Luo Q, Halim A, Song G. Targeting lipid metabolism of cancer cells: A promising therapeutic strategy for cancer. Cancer Lett. 2017;401:39-45. https://doi.org/10.1016/j.canlet.2017.05.002
Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732-749. https://doi.org/10.1038/nrc.2016.89
Lewis CA, Parker SJ, Fiske BP, McCloskey D, Gui DY, Green CR, Vokes NI, Feist AM, Vander Heiden MG, Metallo CM. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol Cell. 2014;55(2):253-263. https://doi.org/10.1016/j.molcel.2014.05.008
Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li JL, Zhang Q, Wakelam MJ, Karpe F, Schulze A, Harris AL. Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014;9(1): 165-349. https://doi.org/10.1016/j.celrep.2014.08.056
Benedetti E, Galzio R, Laurenti G, D’Angelo B, Melchiorre E, Cifone MG, Fanelli F, Muzi P, Coletti G, Alecci M, Sotgiu A, Ceru MP, Cimini A. Lipid metabolism impairment in human gliomas: expression of peroxisomal proteins in human gliomas at different grades of malignancy. Int J Immunopathol Pharmacol. 2010;23(1):235-246. https://doi.org/10.1177/039463201002300121
Grube S, Gottig T, Freitag D, Ewald C, Kalff R, Walter J. Selection of suitable reference genes for expression analysis in human glioma using RT-qPCR. J Neurooncol. 2015;123(1):35-42. https://doi.org/10.1007/s11060-015-1772-7
Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP, Knoblich JA. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501(7467): 373-379. https://doi.org/10.1038/nature12517
Stoll EA, Makin R, Sweet IR, Trevelyan AJ, Miwa S, Horner PJ, Turnbull DM. Neural stem cells in the adult subventricular zone oxidize fatty acids to produce energy and support neurogenic activity. Stem Cells. 2015;33(7):2306-2019. https://doi.org/10.1002/stem.2042
Kambach DM, Halim AS, Cauer AG, Sun Q, Tristan CA, Celiku O, Kesarwala AH, Shankavaram U, Batchelor E, Stommel JM. Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma. Oncotarget. 2017;8(9):14860-14875. https://doi.org/10.18632/oncotarget.14740
Strickland M, Stoll EA. Metabolic reprogramming in glioma. Front Cell Dev Biol. 2017;5:43. https://doi.org/10.3389/fcell.2017.00043
Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010; 102(13):932-941. https://doi.org/10.1093/jnci/djq187
Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599-608. https://doi.org/10.1093/annonc/mdw013
Al-Khallaf H. Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. Cell Biosci. 2017;7:37. https://doi.org/10.1186/s13578-017-0165-3
Narahara K, Kimura S, Kikkawa K, Takahashi Y, Wakita Y, Kasai R, Nagai S, Nishibayashi Y, Kimoto H. Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3. Hum Genet. 1985;71(1):37-40.
Huh TL, Kim YO, Oh IU, Song BJ, Inazawa J. Assignment of the human mitochondrial NAD+ -specific isocitrate dehydrogenase alpha subunit (IDH3A) gene to 15q25.1—>q25.2by in situ hybridization. Genomics. 1996;32(2):295-296. https://doi.org/10.1006/geno.1996.0120
Online Mendelian Inheritance in Man, OMIM. Isocitrate Dehydrogenase 3, Gamma Subunit; IDH3G. 2018. URL: https://www.omim.org/entry/300089
Online Mendelian Inheritance in Man, OMIM. Isocitrate Dehydrogenase 3, Beta Subunit; IDH3B. 2018. URL: https://www.omim.org/entry/604526
Online Mendelian Inheritance in Man, OMIM. Isocitrate Dehydrogenase 3, Alpha Subunit; IDH3A. 2018. URL: https://www.omim.org/entry/601149
Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther. 2015;152:54-62. https://doi.org/10.1016/j.pharmthera.2015.05.003
Fedeles BI, Singh V, Delaney JC, Li D, Essigmann JM. The AlkB Family of Fe(II)/alpha-Ketoglutarate-dependent Dioxygenases: Repairing Nucleic Acid Alkylation Damage and Beyond. J Biol Chem. 2015;290(34): 20734-20742. https://doi.org/10.1074/jbc.R115.656462
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17-30. https://doi.org/10.1016/j.ccr.2010.12.014
Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, Kho EY, Ghosh AP, Kirkman R, Velu S, Dutta S, Chenna B, Rea SL, Mishur RJ, Li Q, Johnson-Pais TL, Guo L, Bae S, Wei S, Block K, Sudarshan S. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 2014;4(11):1290-1298. https://doi.org/10.1158/2159-8290.Cd-13-0696
Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011;25(10):1010-1022. https://doi.org/10.1101/gad.2037511
Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One. 2011;6(5):e19868. https://doi.org/10.1371/journal.pone.0019868
Goryaynov SA, Gol’dberg MF, Golanov AV, Zolotova SV, Shishkina LV, Ryzhova MV, Pitskhelauri DI, Zhukov VY, Usachev DY, Belyaev AY, Kondrashov AV, Shurkhay VA, Potapov AA. The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H). Zh Vopr Neirokhir Im N N Burdenko. 2017;81(3):5-16. https://doi.org/10.17116/neiro20178135-16
Kartashev AV, Yakubovich EI. Geneticheskie markery zlokachestvennyh gliom. Med Academ J. 2016;16(3):64-74. (In Russ.)
Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013;13(5):345. https://doi.org/10.1007/s11910-013-0345-4
Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuro-pathol. 2015;129(6):829-848. https://doi.org/10.1007/s00401-015-1432-1
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483. https://doi.org/10.1038/nature10866
Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, Chi JT, Bigner DD, Vertino PM, Yan H. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 2012;22(12):2339-2355. https://doi.org/10.1101/gr.132738.111
Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014;20(11):2898-2909. https://doi.org/10.1158/1078-0432.Ccr-13-3052
Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, Deimling A, Bendszus M, Wiestler B. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015;5:16238. https://doi.org/10.1038/srep16238
Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Gunel M, Glazer PM, Bindra RS. 2-Hyd-roxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375). https://doi.org/10.1126/scitranslmed.aal2463
Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y. Oncometabolite D-2-Hydro-xyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 2015;13(11): 2353-2361. https://doi.org/10.1016/j.celrep.2015.11.029
Jiang L, Boufersaoui A, Yang C, Ko B, Rakheja D, Guevara G, Hu Z, DeBerardinis RJ. Quantitative metabolic flux analysis reveals an unconventional pathway of fatty acid synthesis in cancer cells deficient for the mitochondrial citrate transport protein. Metab Eng. 2017;43(Pt B): 198-207. https://doi.org/10.1016/j.ymben.2016.11.004
Hirai T, Chida K. Protein kinase Czeta (PKCzeta): activation mechanisms and cellular functions. J Biochem. 2003;133(1):1-7.
Seto KK, Andrulis IL. Atypical protein kinase C zeta: potential player in cell survival and cell migration of ovarian cancer. PLoS One. 2015;10:4:e0123528. https://doi.org/10.1371/journal.pone.0123528
Parker PJ, Justilien V, Riou P, Linch M, Fields AP. Atypical protein kinase Ciota as a human oncogene and therapeutic target. Biochem Pharmacol. 2014;88(1):1-11. https://doi.org/10.1016/j.bcp.2013.10.023
Paul A, Danley M, Saha B, Tawfik O, Paul S. PKCzeta Promotes Breast Cancer Invasion by Regulating Expression of E-cadherin and Zonula Occludens-1 (ZO-1) via NFkappaB-p65. Sci Rep. 2015;5:12520. https://doi.org/10.1038/srep12520
Tejeda-Munoz N, Gonzalez-Aguilar H, Santoyo-Ramos P, Castaneda-Patlan MC, Robles-Flores M. Glycogen synthase kinase 3beta is positively regulated by protein kinase Czeta-mediated phosphorylation induced by Wnt agonists. Mol Cell Biol. 2015;36(5):731-741. https://doi.org/10.1128/mcb.00828-15
Siddique HR, Feldman DE, Chen CL, Punj V, Tokumitsu H, Machida K. NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer. Hepatology. 2015;62(5):1466-1479. https://doi.org/10.1002/hep.27987
Guo H, Gu F, Li W, Zhang B, Niu R, Fu L, Zhang N, Ma Y. Reduction of protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. J Neurochem. 2009;109(1):203-213. https://doi.org/10.1111/j.1471-4159.2009.05946.x
Huang HC, Huang CY, Lin-Shiau SY, Lin JK. Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 glioma invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression. Mol Carcinog. 2009;48(6):517-531. https://doi.org/10.1002/mc.20490
Hartsink-Segers SA, Beaudoin JJ, Luijendijk MW, Exalto C, Pieters R, Den Boer ML. PKCzeta and PKMzeta are overexpressed in TCF3-rearranged paediatric acute lymphoblastic leukaemia and are associated with increased thiopurine sensitivity. Leukemia. 2015;29(2):304-311. https://doi.org/10.1038/leu.2014.210
Wang YX, Zhang XR, Zhang ZJ, Li L, Xi GJ, Wu D, Wang YJ. Protein kinase Mzeta is involved in the modulatory effect of fluoxetine on hippocampal neurogenesis in vitro. Int J Neuropsychopharmacol. 2014; 17(9):1429-1441. https://doi.org/10.1017/s1461145714000364
Ni S, Chen L, Li M, Zhao W, Shan X, Wu M, Cheng J, Liang L, Wang Y, Jiang W, Zhang J, Ni R. PKC iota promotes cellular proliferation by accelerated G1/S transition via interaction with CDK7 in esophageal squamous cell carcinoma. Tumour Biol. 2016;37(10):13799-13809. https://doi.org/10.1007/s13277-016-5193-9
Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, Grudem M, Wahner Hendrickson A, Carlson RE, Barrette B, Karlin N, Fields AP. A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients. Oncology. 2015;88(4):208-213. https://doi.org/10.1159/000369257
Kashihara H, Shimada M, Kurita N, Iwata T, Sato H, Yoshikawa K, Miyatani T, Takasu C, Matsumoto N. Protein kinase Ciota is a new prognostic factor in gastric cancer. Surg Today. 2015;45(6):759-764. https://doi.org/10.1007/s00595-014-1010-5
Rosse C, Lodillinsky C, Fuhrmann L, Nourieh M, Monteiro P, Irondelle M, Lagoutte E, Vacher S, Waharte F, Paul-Gilloteaux P, Romao M, Sengmanivong L, Linch M, van Lint J, Raposo G, Vincent-Salomon A, Bieche I, Parker PJ, Chavrier P. Control of MT1-MMP transport by atypical PKC during breast-cancer progression. Proc Natl Acad Sci USA. 2014;111(18):E1872-E1879. https://doi.org/10.1073/pnas.1400749111
Luo Q, Tang L, Lin H, Huang J, Zhang T, Liu Y, Wang J, Zhan P, Yin X, Su X, Ji Q, Yu D, Xu L. The oncogenic role of PKCiota gene amplification and overexpression in Chinese non-small cell lung cancer. Lung Cancer. 2014;84(2):190-195. https://doi.org/10.1016/j.lungcan.2013.08.029
Baldwin RM, Barrett GM, Parolin DA, Gillies JK, Paget JA, Lavictoire SJ, Gray DA, Lorimer IA. Coordination of glioblastoma cell motility by PKCiota. Mol Cancer. 2010;9:233. https://doi.org/10.1186/1476-4598-9-233
Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P, Goidts V. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. Int J Cancer. 2016;139(8):1776-1787. https://doi.org/10.1002/ijc.30234
McCray AN, Desai S, Acevedo-Duncan M. The interruption of PKC-iota signaling and TRAIL combination therapy against glioblastoma cells. Neurochem Res. 2014;39(9):1691-1701. https://doi.org/10.1007/s11064-014-1361-8
Van Dijk M, Muriana FJ, van Der Hoeven PC, de Widt J, Schaap D, Moolenaar WH, van Blitterswijk WJ. Diacylglycerol generated by exogenous phospholipase C activates the mitogen-activated protein kinase pathway independent of Ras- and phorbol ester-sensitive protein kinase C: dependence on protein kinase C-zeta. Biochem J. 1997;323( Pt 3):693-699.
Chen W, Goff MR, Kuang H, Chen G. Higher protein kinase C zeta in fatty rat liver and its effect on insulin actions in primary hepatocytes. PLoS One. 2015;10(3):e0121890. https://doi.org/10.1371/journal.pone.0121890
Kelly KR, Sung CK, Abbott MJ, Turcotte LP. Phosphatidylinositol 3-kinase-dependent insulin regulation of long-chain fatty acid (LCFA) metabolism in L6 muscle cells: involvement of atypical protein kinase C-zeta in LCFA uptake but not oxidation. J Endocrinol. 2008;198(2):375-384. https://doi.org/10.1677/joe-08-0122
Berra B, Bordoni A, Rapelli S, Biagi PL, Pezzotta S, Malgrassi L, Montorfano G, Hrelia S. Altered membrane lipid composition in a human meningosarcoma. Int J Clin Lab Res. 1994;24(1):54-57.